Soluble PDGFRβ (sPDGFRβ) is released into the bloodstream upon pericyte damage, serving as a peripheral indicator of blood-brain barrier (BBB) pericyte coverage loss. Elevated plasma sPDGFRβ correlates with BBB leakage and cognitive decline trajectories. The mechanism involves ADAM10/ADAM17-mediated ectodomain shedding of PDGFRβ from damaged pericytes. This hypothesis has the strongest evidence base with human validation in Alzheimer's disease (AD) and vascular dementia cohorts. Specificity concerns regarding peripheral PDGFRβ+ cell sources (vascular smooth muscle cells, hepatic stellate cells) are addressable through cell-type-specific validation studies and parallel peripheral biomarker controls.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Pericyte injury"]
B["ADAM10 and ADAM17 activation"]
C["PDGFRbeta ectodomain shedding"]
D["Soluble PDGFRbeta release"]
E["Plasma sPDGFRbeta elevation"]
F["BBB pericyte coverage loss"]
G["Blood-brain barrier leakage"]
H["Cognitive decline"]
I["Neurodegeneration"]
J["AD and vascular dementia progression"]
K["sPDGFRbeta as peripheral biomarker"]
L["ADAM10 and ADAM17 inhibition"]
M["Pericyte protection strategies"]
A --> B --> C --> D --> E
E --> F
F --> G
G --> H
H --> I
I --> J
E --> K
L --> B
M --> A
style A fill:#ef5350
style B fill:#4fc3f7
style C fill:#4fc3f7
style D fill:#4fc3f7
style E fill:#4fc3f7
style F fill:#ef5350
style G fill:#ef5350
style H fill:#ef5350
style I fill:#ef5350
style J fill:#ef5350
style K fill:#81c784
style L fill:#81c784
style M fill:#81c784
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
3 citations3 with PMIDValidation: 0%0 supporting / 3 opposing
✓For(0)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
MECH 3CLIN 0GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
sPDGFRβ elevated in systemic inflammation independ…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Mechanistic Hypotheses: BBB Permeability Biomarkers for Neurodegeneration
Hypothesis 1: Soluble PDGFRβ as a Peripheral Pericyte Degeneration Marker
Title: Circulating Soluble PDGFRβ Reflects Pericyte Loss and Precedes Cognitive Decline in Neurodegeneration
Description: Pericyte degeneration is among the earliest events in Alzheimer's disease (AD) and vascular dementia, preceding amyloid deposition and cognitive symptoms. Damaged pericytes release the ectodomain of platelet-derived growth factor receptor β (sPDGFRβ) into the bloodstream, making it a peripheral indicator o
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation: BBB Permeability Biomarkers for Neurodegeneration
I will systematically evaluate each hypothesis for mechanistic plausibility, specificity, technical feasibility, and potential confounds. Where applicable, I will identify issues that span multiple hypotheses.
Hypothesis 1: Soluble PDGFRβ (Original: 0.82)
Specific Weaknesses
Non-CNS sources of sPDGFRβ: PDGFRβ is expressed on pericytes, vascular smooth muscle cells (VSMCs), cardiac fibroblasts, hepatic stellate cells, and renal mesangial cells. Systemic inflammatory conditions (atherosclerosis, pul
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Biomarker Utility: HIGH — sPDGFRβ functions as a pharmacodynamic/response biomarker rather than a direct therapeutic target. The underlying PDGFRβ signaling axis, however, represents a legitimate therapeutic target.
Therapeutic Approaches: | Strategy | Agent Class | De
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses": [{"title": "Circulating Soluble PDGFRβ Reflects Pericyte Loss and Precedes Cognitive Decline in Neurodegeneration", "description": "Soluble PDGFRβ (sPDGFRβ) is released into the bloodstream upon pericyte damage, serving as a peripheral indicator of blood-brain barrier (BBB) pericyte coverage loss. Elevated plasma sPDGFRβ correlates with BBB leakage and cognitive decline trajectories. The mechanism involves ADAM10/ADAM17-mediated ectodomain shedding of PDGFRβ from damaged pericytes. This hypothesis has the strongest evidence base with human validation in Alzheimer's dise
If circulating sPDGFRβ reflects pericyte loss, then sPDGFRβ levels will correlate with BBB leakage (Qalb, DCE-MRI Ktrans), decrease in brain pericyte coverage (postmortem histology), and predict cognitive decline, independent of amyloid and tau burden.
pendingconf: 0.50
Expected outcome: In matched cohort (n≥60 with PET amyloid/tau, DCE-MRI, plasma sPDGFRβ), high plasma sPDGFRβ (top quartile) associates with elevated Qalb (OR>3), reduced pericyte coverage on biopsy (40-60% reduction), and faster MMSE decline (2x rate) over 2 years, independent of amyloid PET SUVR.
Falsified by: sPDGFRβ does not correlate with BBB leakage, pericyte coverage, or cognitive trajectory after adjustment for amyloid/tau burden; levels are entirely explained by neurodegenerative rather than pericyte-specific processes.
Method: Prospective cohort with amyloid PET, tau PET, DCE-MRI, plasma sPDGFRβ (ELISA), and neuropsych testing; immunohistochemistry on available biopsy/autopsy tissue (n≥30) for pericyte markers (PDGFRβ, NG2).
If sPDGFRβ is a pericyte-loss biomarker, then declining sPDGFRβ over time will indicate improving pericyte function and better clinical outcomes in intervention studies targeting pericyte health (e.g., BMP4, retinoic acid derivatives).
pendingconf: 0.50
Expected outcome: In pericyte-targeting trial (e.g.,Subjects receiving BMP4 or RA derivative vs placebo), plasma sPDGFRβ decreases in treatment arm (>30% reduction at 6 months) and correlates with improved BBB integrity (DCE-MRI Ktrans normalization) and slowed cognitive decline.
Falsified by: sPDGFRβ does not change with pericyte-targeting intervention; BBB integrity and cognitive outcomes are unaffected by pericyte modulation despite sPDGFRβ changes, indicating sPDGFRβ is not a causal pericyte marker.
Method: Phase 2 trial with pericyte-targeted intervention; plasma sPDGFRβ, BBB MRI endpoints, and cognitive battery at baseline/3/6/12 months; biomarker-drug response correlation analysis.